Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH)
Learn to design drug development programs for First-in-Human (FIH) success with biomarkers, PK/PD modeling, and…
CertaraAugust 29, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
CertaraAugust 13, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
MIDD Strategies for Preclinical and Clinical Translation: A Collaboration Between Clinical Pharmacologists and Modeling Disciplines
Learn how clinical pharmacologists and modeling experts collaborate to improve preclinical-to-clinical translation.
CertaraJuly 29, 2025
ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered
ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…
CertaraJuly 23, 2025
